Search for content, post, videos

XNK Therapeutics appoints new CMO and CSO

Johan Aschan and Michael Uhlin

XNK Therapeutics has announced the appointment of Dr. Johan Aschan as Chief Medical Officer, effective July 1st, and Professor Michael Uhlin as Chief Scientific Officer, effective August 1st.

Michael Uhlin will be responsible for defining, implementing, and developing the company’s scientific strategy. He will lead a team involved in R&D and manufacturing with focus on platform development as well as improving production processes and executing operational research plans.

“We are extremely pleased to welcome Michael to XNK Therapeutics. With his long scientific experience and excellent track record within clinical immunology, Michael will be instrumental in the development of the scientific strategy for the company’s NK cell-based therapies,” says Johan Liwing, CEO of XNK Therapeutics.

Michael Uhlin

Professor Uhlin received his master’s degree in medical research with a focus on biomedicine from Karolinska Institutet (KI) in 2002 and his PhD in Infection Biology from KI in 2006. Since then, he has held several senior positions primarily within clinical immunology and cellular therapy at KI and Karolinska University Hospital, Stockholm, including serving as Head of Clinical Immunology, Department of Clinical Immunology and Transfusion Medicine at the Karolinska University Hospital.

“XNK is a leading company in an exciting field of biotechnology, currently getting a lot of international attention,” says Uhlin. “I am very excited to join XNK to further develop its scientific strategy.”

Johan Aschan

Johan Aschan received his MD from Karolinska Institutet (KI) in 1985 and his PhD in Clinical Immunology from KI in 1994. He has extensive experience from work within the field of allogenic stem cell transplantation at the Karolinska University Hospital in Huddinge, Sweden, and from various leadership roles within hematology and oncology at Janssen. Most recently, prior to joining XNK, Dr. Aschan was Global Clinical Lead within Clinical Development at the Swedish biotech company Oncopeptides.

“Johan has a superb background within hematology and oncology and is ideally suited for the present position within the XNK team,” says Johan Liwing, CEO of XNK Therapeutics. “XNK is an immunotherapy company focused on treating cancer by developing novel NK cell-based therapies. Johan’s depth of experience will help us in the clinical development of our leading investigational drug candidate.”

“XNK is an exciting company with a novel approach to autologous NK cell-based therapies that has the potential to significantly advance the fight against cancer,” says Dr. Johan Aschan. “I am very happy to join XNK and further develop the company’s clinical program.”

Photo of Johan Aschan and Michael Uhlin